
### [NCIT:C27632](http://purl.obolibrary.org/obo/NCIT_C27632)
**Label:** Transplant-Related Malignant Neoplasm

**Subclasses:** [NCIT:C27640](http://purl.obolibrary.org/obo/NCIT_C27640) (Transplant-Related Kaposi Sarcoma), [NCIT:C27695](http://purl.obolibrary.org/obo/NCIT_C27695) (EBV-Related Clonal Post-Transplant Lymphoproliferative Disorder), [NCIT:C7249](http://purl.obolibrary.org/obo/NCIT_C7249) (Immunoblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7238](http://purl.obolibrary.org/obo/NCIT_C7238) (Monomorphic T/NK-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7248](http://purl.obolibrary.org/obo/NCIT_C7248) (Centroblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7237](http://purl.obolibrary.org/obo/NCIT_C7237) (Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7239](http://purl.obolibrary.org/obo/NCIT_C7239) (Hodgkin-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C7245](http://purl.obolibrary.org/obo/NCIT_C7245) (Burkitt-Like Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27638](http://purl.obolibrary.org/obo/NCIT_C27638) (Transplant-Related Renal Cell Carcinoma), [NCIT:C27637](http://purl.obolibrary.org/obo/NCIT_C27637) (Transplant-Related Lung Carcinoma), [NCIT:C7233](http://purl.obolibrary.org/obo/NCIT_C7233) (Monomorphic Post-Transplant Lymphoproliferative Disorder), [NCIT:C7244](http://purl.obolibrary.org/obo/NCIT_C7244) (Burkitt Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7247](http://purl.obolibrary.org/obo/NCIT_C7247) (Anaplastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27639](http://purl.obolibrary.org/obo/NCIT_C27639) (Transplant-Related Hematologic Malignancy), [NCIT:C7246](http://purl.obolibrary.org/obo/NCIT_C7246) (Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7241](http://purl.obolibrary.org/obo/NCIT_C7241) (Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C27634](http://purl.obolibrary.org/obo/NCIT_C27634) (Transplant-Related Bladder Urothelial Carcinoma), [NCIT:C27633](http://purl.obolibrary.org/obo/NCIT_C27633) (Transplant-Related Carcinoma), [NCIT:C7240](http://purl.obolibrary.org/obo/NCIT_C7240) (Plasma Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7243](http://purl.obolibrary.org/obo/NCIT_C7243) (Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder), [NCIT:C27636](http://purl.obolibrary.org/obo/NCIT_C27636) (Transplant-Related Skin Squamous Cell Carcinoma), [NCIT:C7242](http://purl.obolibrary.org/obo/NCIT_C7242) (Plasma Cell Myeloma Post-Transplant Lymphoproliferative Disorder), [NCIT:C27635](http://purl.obolibrary.org/obo/NCIT_C27635) (Transplant-Related Hepatocellular Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39856](http://purl.obolibrary.org/obo/NCIT_C39856) (Urothelial Dysplasia))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39845](http://purl.obolibrary.org/obo/NCIT_C39845) (Bladder Urachal Squamous Cell Carcinoma))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39844](http://purl.obolibrary.org/obo/NCIT_C39844) (Bladder Urachal Urothelial Carcinoma))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39834](http://purl.obolibrary.org/obo/NCIT_C39834) (Bladder Squamous Papilloma))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39833](http://purl.obolibrary.org/obo/NCIT_C39833) (Schistosoma Hematobium-Related Bladder Verrucous Carcinoma))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39829](http://purl.obolibrary.org/obo/NCIT_C39829) (Infiltrating Bladder Urothelial Carcinoma with Giant Cells))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39826](http://purl.obolibrary.org/obo/NCIT_C39826) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant without Heterologous Elements))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39825](http://purl.obolibrary.org/obo/NCIT_C39825) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant with Heterologous Elements))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39821](http://purl.obolibrary.org/obo/NCIT_C39821) (Infiltrating Bladder Lymphoepithelioma-Like Carcinoma))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39820](http://purl.obolibrary.org/obo/NCIT_C39820) (Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39819](http://purl.obolibrary.org/obo/NCIT_C39819) (Infiltrating Bladder Urothelial Carcinoma, Nested Variant))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39818](http://purl.obolibrary.org/obo/NCIT_C39818) (Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39817](http://purl.obolibrary.org/obo/NCIT_C39817) (Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation))) 60.82%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C39816](http://purl.obolibrary.org/obo/NCIT_C39816) (Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation))) 60.82%


